Search research articles
Contact Us
Filters
Showing results (31-40 of 37) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 37 results.
Lancet (London, England)
|
July 30, 1994
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis
T Moreau, J Thorpe, D Miller, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
January 1, 1989
Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone
J Kesselring, D H Miller, D G MacManus, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 1, 1996
CAMPATH-IH in multiple sclerosis
T Moreau, A Coles, M Wing, et al.
European Journal of Neurology
|
September 18, 2008
EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases
I Elovaara, S Apostolski, P van Doorn, et al.
Neurology
|
July 29, 2011
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
M Cossburn, A A Pace, J Jones, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 23, 2002
Intravenous immunoglobulin in neurological disease: a specialist review
C M Wiles, P Brown, H Chapel, et al.
Annals of the Rheumatic Diseases
|
August 21, 2010
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs
G K Bertsias, J P A Ioannidis, M Aringer, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 37) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 37 results.
Lancet (London, England)
|
July 30, 1994
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis
T Moreau, J Thorpe, D Miller, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
January 1, 1989
Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone
J Kesselring, D H Miller, D G MacManus, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 1, 1996
CAMPATH-IH in multiple sclerosis
T Moreau, A Coles, M Wing, et al.
European Journal of Neurology
|
September 18, 2008
EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases
I Elovaara, S Apostolski, P van Doorn, et al.
Neurology
|
July 29, 2011
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
M Cossburn, A A Pace, J Jones, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 23, 2002
Intravenous immunoglobulin in neurological disease: a specialist review
C M Wiles, P Brown, H Chapel, et al.
Annals of the Rheumatic Diseases
|
August 21, 2010
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs
G K Bertsias, J P A Ioannidis, M Aringer, et al.
Page
of 4